SCHEMBL21212296

SCHEMBL21212296

COc1c(S)cccc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.43
P2RX7 Q99572 1/20 0.38
HSD11B1 P28845 3/20 0.37
AR P10275 3/20 0.36
NFE2L2 Q16236 1/20 0.35
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
CTSA P10619 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
PGR P06401 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16829403 0.87 CTSS (0.44) CTSSP2RX7HSD11B1ARNFE2L2
SCHEMBL6041965 0.83 CA2 (0.41) CTSSALDH1A1KDM4EMAPK1SMN1; SMN2
SCHEMBL10451316 0.79 AR (0.49) CTSSARNFE2L2ALDH1A1KDM4E
SCHEMBL22208564 0.79 AR (0.44) CTSSP2RX7HSD11B1ARNFE2L2
SCHEMBL31697313 0.79 AR (0.44) CTSSP2RX7HSD11B1ARNFE2L2
SCHEMBL23977880 0.79 SCN8A (0.44) CTSSP2RX7HSD11B1ARNFE2L2
SCHEMBL29749364 0.79 AR (0.49) CTSSARNFE2L2ALDH1A1KDM4E
SCHEMBL27439941 0.79 P2RX7 (0.46) CTSSP2RX7ARSMN1; SMN2CYP1A2
SCHEMBL2783256 0.78 ULK1 (0.40) CTSSP2RX7HSD11B1ARNFE2L2
SCHEMBL9820988 0.78 CA2 (0.47) CTSSARALDH1A1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 WO disclosed